Evercore ISI raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $392 from $360 and keeps an Outperform rating on the shares following what the firm calls “another solid quarter.” The stock was trading off at the open, however, which the firm sees as likely driven by fading near term M&A speculation and cash utilization. The firm sees post-earnings weakness as a buying opportunity, noting that it updated its model with increased revenue projections off a strong quarter and 4% price increase.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal price target raised to $400 from $390 at H.C. Wainwright
- Madrigal Pharmaceuticals price target lowered to $154 from $155 at BofA
- Madrigal Pharmaceuticals sees Q4 Rezdiffra revenue $100M-$103M
- Oppenheimer starts Sagimet with Outperform on ‘underappreciated opportunity’
- Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities